Group items tagged

The Health Committee's new report has reminded the government of a much-needed pharmacy workforce plan to support recruitment, training, and retention of staff. The report makes a number of recommendations to optimise workloads across primary care, reduce pressure on general practice and hospitals, and support the integrated care systems. It also recognises the potential of pharmacist independent prescribers to support patient care, backed by appropriate supervision, training, and opportunities for professional development. RPS England gave evidence to MPs on the Committee at a public hearing in May, highlighting key issues to support the pharmacy workforce. RPS director for England, Ravi Sharma, said: "Today's report underlines the urgent need for the Government to set out a comprehensive workforce plan for health and care. "It rightly recognises that boosting recruitment and retention, supporting staff wellbeing, fostering inclusion and diversity, and investing in education and training will be crucial to the future of the NHS.

In a recent interview with The Telegraph, health secretary Steve Barclay stated that he has asked his officials within DHSC to look at a "pharmacy first" approach to alleviate pressures on A&E departments in order to avoid the widely predicted NHS winter crisis. On the face of it, this a welcome if long overdue recognition that community pharmacy is an essential part of our national healthcare infrastructure alongside our GP and A&E colleagues. But let's not get carried away - we have had lots of praise from politicians in the past which have not then been backed by firm commitments for a sustainable future for the network. Could this be a turning point? I hope so, but I am not confident it will be. I fear this may turn out to be another emergency stop-gap measure which does nothing to secure the long-term viability of the sector in England. The role of community pharmacy during the recent Covid pandemic demonstrated clearly how important we are to ensure people have easy access to essential healthcare support, advice and services. The NHS winter crisis can only be avoided or at least mitigated if the potential of the community pharmacy network to provide more patient care services is unlocked and that Barclay requires you to end pharmacy funding austerity and start investing. The Treasury will no doubt say there is no more money, but what then the alternative other than a NHS winter crisis? And, of course, treating people in secondary care settings is far more costly than community pharmacy based interventions.

Rising chronic illnesses and an aging population are threatening to bankrupt the National Health Service, Labour's Shadow Health Secretary Wes Streeting has said on October 11. Streeting announced a substantial £1.1 billion injection to strengthen the NHS with the goal of clearing the backlog and introducing additional clinics on evenings and weekends. The frontbencher outlined a reform agenda to ensure NHS is back on its head for the future of healthcare in the UK. Streeting said that a Labour government will not waste "money we don't have"- instead aims to revolutionise the NHS by shifting its focus from hospitals to communities. "Our emphasis is on transitioning from an analogue to a digital framework and prioritising prevention over sickness-oriented healthcare," he noted.

A report released by the Independent Commission has blamed Brexit supply issues for medicine shortages. NHS is forced to pay extortionate prices to fulfil the demand for vital antibiotics, anti-depressants, Attention Deficit Hyperactivity Disorder (ADHD), and Hormone Replacement Therapy (HRT) drugs. The report highlights the impact of affected medicine supply issues on community pharmacies and patients. Janet Morrison, the chief executive of Community Pharmacy England, backed the report and said that the "medicine shortages and market instability appear to be as bad as they have ever been". She also explained how the Ukraine conflict, the COVID-19 pandemic, and broader economic instability also play a major factor in the situation.

Scottish community pharmacies will now hold two Naloxone kits, available in either nasal spray or injectable form, essential for reversing opioid overdoses. The Emergency Access Naloxone Scheme, which is backed by £300,000 of Scottish Government funding, began on Monday (30 October). Drugs and Alcohol Policy Minister Elena Whitham said, "Through our National Mission to reduce drug deaths and harms, we have invested more than £3 million in widening access to Naloxone, including through our emergency services." Witham said this new nationwide service is a welcome addition to existing services. "Police Scotland recently completed a force-wide rollout to 12,500 officers who have used the kits more than 300 times. According to the most recent statistics, 70 per cent of those who are at risk of opioid overdose are being provided with a lifesaving kit," she added. "It provides a substantial increase in life-saving emergency access and I'm grateful to all those in community pharmacies who are supporting our £250 million National Mission to reduce drug deaths," Whitham said.

Community Pharmacy England (CPE) is seeking views from all community pharmacy owners about the pressures faced this autumn season. A survey has been launched as the "November Pre-Committee Opinion Poll" until 6 November to seek views from independents and non-Company Chemists' Association (CCA) members. The results of the poll will be sent to the head offices of CCA multiples next week for discussion at the November Committee Meeting. CPE confirmed: "The results of these polls and the outcomes of the meeting will be reported back to the sector afterwards. They said that the survey "will be used to feed into our ongoing work to press for an uplift to core funding by enhancing our evidence base of what pharmacy owners are experiencing."

MP Steve Brine, the chair of the health and care committee, said that the healthcare in the UK "doesn't work without pharmacy". The inquiry focuses on addressing current issues, particularly around the "funding model, digital infrastructure and workforce recruitment, training and retention." Brine said at the Sigma annual conference on Sunday, that he wants to "focus on the sector", and "drill down into some of the challenges and potential" that lies ahead. "The Health and Social Care Committee, we think about much of our work through the lens of pharmacy, what role it plays, the quality of care that it delivers, and the potential for it to do more," said Brine. He further said that he wants to "build on the groundwork" and to "cover as many of the different pharmacy services within the pharmacy sector as we can, so pharmacy in our communities, in hospitals and general practice".

The Health and Social Care Select Committee (HSCC) on Tuesday held the first session in their pharmacy inquiry, with a panel of experts discussing the key issues facing community pharmacies in the country. Representatives from community pharmacy associations highlighted some of their biggest challenges and their vision for the future, as well as actions that government and NHS England can take to address those challenges for a better future for the sector. Opening the session, the Committee's vice-chair, Rachel Maskell MP, asked the representatives if they felt the government was ambitious enough in what it believes community pharmacy can do to address NHS pressures, or are pharmacists being held back by issues around workforce funding, contracting, and technological changes. Malcolm Harrison, Chief Executive, Company Chemists' Association (CCA), expressed that the government is not ambitious enough, saying "there's always opportunity to be more ambitious".

When I was asked by fellow independent contractors to join the Review Steering Group (RSG) back in late 2020, I said yes, because I wanted, fundamentally, to look for some ways to improve both LPCs and PSNC. Through my experiences with Greater Manchester LPC I had seen the sorts of changes that LPCs could make and the positive impact that those had on local engagement and in allowing us to do more to support contractors: I wanted to help share what we had learned with the rest of the country. I was pretty sure that the national negotiator could make some positive changes as well. It took longer than I had hoped. And it was a lot harder than I had imagined - not least because of the extent of some of the divisions within our sector - but after 15 months of hard work, I'm pleased with where we have got to, and I believe the 37 changes being proposed will help all contractors. Consensus is not a sexy word. It is not something that fires up our imaginations or that we put on our list of key work objectives for the year. It is also not something that might come naturally to us as independent contractors. But consensus is something that matters. It is the thing that allows us, as a vibrant and diverse group of businesses, to see beyond our differences and to fight together for outcomes that benefit every single one of us. Consensus is also the thing that the RSG has been relentlessly focused on throughout its work, and it's at the heart of what will give our LPCs and PSNC a stronger voice for community pharmacy in the future.

Thirty-five generic drug manufacturers will make a more affordable version of Pfizer's anti-Covid pill for the world's poorer nations, in licensing deals announced Thursday (17) by a UN-backed organisation. The global Medicines Patent Pool (MPP) signed agreements with three dozen manufacturers to produce the oral Covid-19 treatment nirmatrelvir for supply in 95 low- and middle-income countries. US pharmaceutical giant Pfizer signed a licence agreement with the MPP in November. The MPP, in turn, issued sub-licences to the generic drugs makers. The deals announced Thursday will "help ensure access to our oral Covid-19 treatment for patients in need around the world", said Pfizer chairman Albert Bourla.

Prostate cancer is the most common cancer among men in the United Kingdom, affecting nearly 50,000 men yearly. Combined with the challenges faced across healthcare during COVID-19, new figures show that prostate cancer accounts for a third of cancers not treated due to the pandemic, with 14,000 'missing patients' believed to have not undergone treatment since April 2020. It is more urgent than ever that men are encouraged to get checked, as any set-backs in diagnosis can reduce the pathways available, in turn affecting health outcomes. Community pharmacy teams play a crucial role in signposting the help available for men who may be concerned about their health. Therefore, it is vital that pharmacy teams have access to the information they need to correctly direct men to seek prostate cancer guidance. By maximising the trusted relationship between patients and their pharmacists, more can be done to identify the warning signs, helping men to get an earlier diagnosis.

The Pharmacists' Defence Association (PDA) has raised concern over the Health Education England (HEE)'s decision on cutting funding to independent prescribing training. The HEE has reportedly decided that no funding will be available to back-fill trainees undertaking the pharmacist independent prescribing (PIP) qualification, or for the supervision of trainees by DPPs and DMPs. The PDA noted that, whilst all successful trainee pharmacists will be entering the GPhC register as independent prescribers from 2026, the existing pharmacist workforce is reliant on opportunities to undertake prescriber training through release from their employment, and the ability to secure a Designated Medical Practitioner (DMP) or Designated Prescribing Practitioner (DPP) to support the 90 days of supervised practice required. The association said it has already heard examples of potential DMPs or DPPs requesting a significant fee from trainees before they will provide supervision, adding that meeting that request is not an option for many. "This latest decision threatens to undermine the availability of the large numbers of pharmacists seeing supervisors as more IP training becomes available," it said in a statement.

The National Institute for Health and Care Excellence (NICE) has recommended abemaciclib also called Verzenios, made by Eli Lilly, for people with hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence who have had surgery to remove their tumour. The clinical trial result showed that people having abemaciclib with hormone therapy had a more than 30 per cent better chance of their cancer not coming back following surgery compared with people having hormone therapy alone. Helen Knight, interim director of medicines evaluation at NICE, said: "Today's positive draft recommendation, which comes less than a month after abemaciclib received its licence, is fantastic news. The fact that we have been able to produce draft recommendations so quickly is testament to the success of our ambition to support patient access to clinically and cost effective treatments as early as possible. "Until now there have been no targeted treatments for people with this type of breast cancer. Abemaciclib with hormone therapy represents a significant improvement in how it is treated because being able to have a targeted treatment earlier after surgery will increase the chance of curing the disease and reduce the likelihood of developing incurable advanced disease."

We all know that clothes can make us look and feel good. But did you know that they can also be used to relieve some common health issues? That's right - by choosing the right fabrics and materials, you can help alleviate conditions like skin irritations, back pain, and even headaches. So the next time you're feeling under the weather, reach for your wardrobe first - it just might hold the key to feeling better. COMPRESSION SOCKS FOR DIABETES Compression socks for diabetes have become an invaluable tool for people with diabetes to keep their lower legs healthy. Wearing compression socks can help increase circulation in diabetic patients, which is incredibly important for the health of their feet and ankles. Additionally, if the patient suffers from swelling or poor blood circulation - compression socks can help reduce those negative side effects. As a result of wearing these specialty socks, many diabetics are kept more comfortable and experience less fatigue in their legs throughout the day. With many different sizes and varieties available - it's easy for anyone suffering from diabetes to find the perfect pair of compression socks to suit their specific needs and lifestyle. There are various diabetic stockings designed for men and women. Take the time to find the right pair for you.

After you've had surgery, it's normal to feel a little anxious about the recovery process. But there are some things you can do to help make sure everything goes smoothly. Here are four important pieces of postoperative advice that will help you heal quickly and avoid any complications. Follow these tips and you'll be on your way to a full recovery in no time. FOLLOW YOUR DOCTOR'S ORDERS No matter how minor the operation, following your doctor's orders after surgery is essential to a speedy and successful recovery. Doing the right things like following a balanced diet, taking the recommended amount of medications, and avoiding strenuous activity can help minimize complications, reduce pain, and speed up healing. Furthermore, consistent follow-up visits with your doctor and timely scheduling of any necessary tests ensure that any post-operative problems are addressed in their early stages when they are easiest to treat. The people behind www.alamoplasticsurgery.com note that failing to take your doctor's instructions seriously can have a significant impact on your overall recovery time, jeopardize the long-term outcome of your treatment, or even lead to additional procedures. To ensure you make the most out of your surgery experience - listen to what your doctor has to say! GET PLENTY OF REST Getting a full night's rest after the surgery is key to a successful recovery. During recovery, your body is working overtime to heal and repair itself, so by getting plenty of rest, you'll give it the best opportunity to do this. Not only that - research has shown that getting lots of sleep may help support important bodily functions related to healing such as immune response and inflammation control. Listen to your doctor's advice post-surgery and make sure you get enough sleep - providing your body with the downtime it needs will ultimately speed up the healing process and help ensure you get back on your feet soon. When it comes to recovering from surgery,

Community pharmacists in England have slammed the government's latest decision to reduce the number of people who get a free winter flu jab in the 2022-23 flu season, as concerns related to Covid-19 still exist. This follows a letter from the NHS England and NHS Improvement (NHSE&I) to clinicians, which stated that the flu vaccination service in 2022-23 will be offered to patient groups eligible in line with pre-pandemic recommendations. The eligibility was widened significantly after the pandemic struck in 2020 to help reduce the death toll from the Covid-19. With the change in place people aged 50-64 and schoolchildren aged 11-15 will not be eligible to receive the free jabs on the NHS next winter, pushing millions of people to pay for their jabs privately. It further recommended that vaccination for frontline healthcare workers and social care workers should be provided by employers as part of the organisation's policy to prevent the transmission of infection.

It's 2022 and data is everything, isn't it? Advertising, decision-making, you name it, data is behind it. What if an ePharmacy could use its own data as an asset? If you knew that sooner or later, you'll be able to turn your data into a revenue stream, wouldn't that be something? And this is exactly what Convert Group does. Convert Group offers the complete eCommerce SaaS ecosystem that helps ePharmacists and brands grow sales, streamline collaboration, and seize data monetization opportunities. Built for scale, Convert Group's platform leverages automation and offers a unique user experience backed by our leading eCommerce team.

British drugmaker GSK has signed deals with three companies allowing them to make inexpensive generic versions of its long-acting HIV preventive medicine for use in lower-income countries, where the majority of new HIV cases occur. The injected drug cabotegravir is approved by regulators in Britain and the United States. Last July, GSK announced a program with the United Nations-backed healthcare organisation, the Medicines Patent Pool, aiming to get poor countries access to new HIV therapies far earlier than they did for previous HIV medicines. During the HIV/AIDs epidemic in Africa in the 1990s and early 2000s, in which many millions of people died, treatments used widely in wealthy countries were unavailable on the continent. GSK said last year the new program could result in the generic form of its injection being available in lower-income countries beginning in 2026. The drugmaker's HIV treatment division, ViiV Healthcare, said in a statement on Wednesday it had issued voluntary licenses - waiving intellectual property rights - to Aurobindo, Cipla and Viatris, which will manufacture the generic versions of injectable cabotegravir.

Recently, the English Health Secretary has talked about introducing a 'Pharmacy First' model similar to that which exists in Scotland. This would be a win-win outcome providing people with better access to essential healthcare support, advice and treatment whilst relieving strain on other parts of the NHS, not least GPs and A&E. It is a no-brainer and yet despite a few media headlines there are still no firm proposals on the table to make this a reality. It surely cannot be right that you can receive a broad range of patient care services in Scotland which are not available in England. It works well in Scotland, Wales is keen to develop more pharmacy-based services and Northern Ireland, leaving aside the current funding dispute, has had a minor ailments service for many years. If the English Health Secretary is sincere in his interest in adopting an English version of the Scottish model, then there are critical aspects he needs to consider. Firstly, start with the patient journey through the healthcare ecosystem from illness prevention through to long-term condition management. What is the role of community pharmacy and how do we guide people to seek support from the most appropriate healthcare professional? What is the vision for community pharmacy delivering patient care in the next decade? The lesson from Scotland is that the government needs to sit down with the sector and map that out together. There are no quick fix overnight solutions. This needs to be a long-term commitment backed by adequate funding. Supervision regulations need to change and there needs to be a thought through workforce strategy which avoids community pharmacy shortages as that does nothing to deliver improved patient outcomes.

John Dawson, the founder and former CEO of Alliance Pharma, has donated £5million to the University of Sunderland towards the creation of a new drug research centre. The donation - the biggest in the university's history - will create the John Dawson Drug Discovery and Development Research Institute to improve health and wellbeing of millions of people worldwide. The new centre has been named after the pharmaceutical entrepreneur and Sunderland graduate who, alongside wife Sam, has provided the funding. He and Sam were on Thursday (April 20) joined by specially invited guests from across the region's health, education, and business communities, to launch the Institute housed in the University's Sciences Complex. Unveiling a plaque inside the building, John said: "It's an absolute honour and privilege to be able to launch the new Drug Discovery and Development Research Institute at the University of Sunderland today. "It's been wonderful to be back on the campus and see the incredible developments that have taken place since I studied pharmacy here more than 50 years ago. "I was immediately impressed at what has been achieved in that intervening half-century and I've been delighted to assist the University continue its development, particularly in the health arena. "I hope the launch of this institute will mark the next phase in the University's evolution and I'm very much looking forward to working with the team as they bring their projects to fruition."